title: Clinicopathological and prognostic significance of Oct-4 expression in patients with non-small cell lung cancer: a systematic review and meta-analysis.
abstract: BACKGROUND
  Octamer-binding transcription factor 4 (Oct-4) has been identified to participate in the tumorigenicity and malignancy of non-small cell lung cancer (NSCLC). However, its definite prognostic roles in NSCLC still remain a debate. Therefore, we conducted this meta-analysis to evaluate the prognostic value of Oct-4 expression in NSCLC and its relationship to some major clinicopathological characteristics.
  
  
  METHODS
  A comprehensive literature retrieval was performed in PubMed, EMBASE and the Web of Science to identify the full-text articles that met our eligibility criteria. Odds ratio (OR) with 95% confidence interval (CI) severed as the summarized statistics for clinicopathological assessments, and hazard ratio (HR) with 95% CI served as the summarized statistics for prognostic assessments. Q-test and I(2)-statistic were used to evaluate the level of heterogeneity. Potential publication bias was detected by both Begg's test and Egger's test.
  
  
  RESULTS
  There were 16 retried articles with 1,363 NSCLC cases included into this meta-analysis. Oct-4 expression was found to be significantly associated with the unfavorable outcomes for differentiation degree (OR: 3.065; 95% CI: 1.568-5.957; P=0.001), TNM stage (OR: 3.695; 95% CI: 2.252-6.063; P<0.001) and lymphatic metastasis (OR: 2.372; 95% CI: 1.504-3.742; P<0.001), but not associated with the histological subtypes, gender, age and smoking status. Oct-4 expression was also significantly associated with the poor prognosis of NSCLC (HR: 3.030; 95% CI: 2.283-4.021; P<0.001). The prognostic roles of Oct-4 expression in NSCLC still remained statistically reliable in the subgroups stratified by statistical analysis, patients' origins, positively-stained sites and histological subtypes.
  
  
  CONCLUSIONS
  Our meta-analysis indicates that Oct-4 can serve as a strong biomarker predicting the poor clinicopathological and prognostic characteristics of NSCLC. More high-quality studies based on a large sample size will be very helpful to further validate and modify our findings in the future.
authors: Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.
authors: Shuang-Jiang
authors: SJ
authors: Li
authors: Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.
authors: Jian
authors: J
authors: Huang
authors: Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.
authors: Xu-Dong
authors: XD
authors: Zhou
authors: Lung Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, China.
authors: Wen-Biao
authors: WB
authors: Zhang
authors: Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.
authors: Yu-Tian
authors: YT
authors: Lai
authors: Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.
authors: Guo-Wei
authors: GW
authors: Che
keywords: Octamer-binding transcription factor 4 (Oct-4); meta-analysis; non-small cell lung cancer (NSCLC); prognosis